CIK 0001868279 · Non-accelerated filer<br>Emerging growth company
ArriVent BioPharma, Inc.
Sign in to watch- Ticker
- AVBP
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- Phone
- 240-780-6356
- Business address
- 18 CAMPUS BLVD., SUITE 100, NEWTOWN SQUARE, PA, 19073-3269
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise | +2,050 | $2.28 | $5K | 126,633 |
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise | +2,600 | $2.28 | $6K | 129,233 |
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise | +6,503 | $2.28 | $15K | 135,736 |
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −2,050 | 410 | ||
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −2,600 | 12,873 | ||
| 2025-07-11 | LaChapelle Robin Chief Operating Officer | Option exercise · Stock Option (right to buy) | −6,503 | 6,370 | ||
| 2025-06-18 | Parsey Merdad Director | Grant or award · Non-Qualified Stock Option (right to buy) | +15,502 | 15,502 | ||
| 2025-06-18 | Peterson Kristine Director | Grant or award · Non-Qualified Stock Option (right to buy) | +15,502 | 15,502 | ||
| 2025-06-18 | Hohneker John Director | Grant or award · Non-Qualified Stock Option (right to buy) | +15,502 | 15,502 | ||
| 2025-06-18 | Nolet Chris Director | Grant or award · Non-Qualified Stock Option (right to buy) | +15,502 | 15,502 | ||
| 2025-04-28 | Parsey Merdad Director | Grant or award · Stock Option (right to buy) | +28,346 | 28,346 | ||
| 2025-02-03 | Yao Zhengbin President and CEO | Grant or award · Stock Option (right to buy) | +380,000 | 380,000 | ||
| 2025-02-03 | Lutzker Stuart President of R&D | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2025-02-03 | LaChapelle Robin Chief Operating Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2025-02-03 | Kung Winston Chief Financial Officer | Grant or award · Stock Option (right to buy) | +120,000 | 120,000 | ||
| 2025-02-03 | Kastenmayer James Paul General Counsel | Grant or award · Stock Option (right to buy) | +102,000 | 102,000 | ||
| 2024-09-19 | LaChapelle Robin Chief Operating Officer | Option exercise | +2,700 | $6.24 | $17K | 99,717 |
| 2024-09-19 | LaChapelle Robin Chief Operating Officer | Option exercise | +2,867 | $2.28 | $7K | 102,584 |
| 2024-09-19 | LaChapelle Robin Chief Operating Officer | Option exercise | +7,164 | $2.28 | $16K | 109,748 |
| 2024-09-19 | LaChapelle Robin Chief Operating Officer | Option exercise | +2,471 | $2.28 | $6K | 112,219 |
Page 2 of 4 · 78 trades